Samuel Dubinsky

Samuel Dubinsky

Auto-generated profile, based on publicly available information

Samuel Dubinsky

Department of Critical Care Dalhousie University Halifax Nova Scotia Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
AGArvind Grewal
Arvind Grewal
PTPierre Thabet
Pierre Thabet
SDSamuel Dubinsky
Samuel Dubinsky
DPDebanjali Purkayastha
Debanjali Purkayastha
KWKristy Wong
Kristy Wong
SKSalmaan Kanji
Salmaan Kanji

10 May 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
SDSamuel Dubinsky
Samuel Dubinsky
ATAlia Thawer
Alia Thawer
AMAnne G. McLeod
Anne G. McLeod
TMThomas Roydon McFarlane
Thomas Roydon McFarlane
Urban EmmeneggerUrban Emmenegger
Urban Emmenegger

5 February 2026 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
SDSamuel Dubinsky
Samuel Dubinsky
MMMark McIntyre
Mark McIntyre
MKMin-Soo Kim
Min-Soo Kim
LHLaura Hawryluk
Laura Hawryluk
AEAndrea Edginton
Andrea Edginton

1 October 2026 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
PDF file
HHH. Rhodes Hambrick
H. Rhodes Hambrick
SDSamuel Dubinsky
Samuel Dubinsky
DQDanica Quickfall
Danica Quickfall
SRShannon Reinert
Shannon Reinert
SGSonya Tang Girdwood
Sonya Tang Girdwood
GSGideon Stitt
Gideon Stitt
Introduction: Evidence‐based dosing guidance for medications in critically ill patients with acute kidney injury (AKI) and receiving continuous kidney replacement therapy (CKRT) is limited. Freely available large language models (LLMs) can generate confident, human‐like outputs. The accuracy and reproducibility of LLMs in providing precision drug dosing recommendations in the setting of AKI and CKRT have not been evaluated. Objectives: We sought to characterize literature concordance and internal consistency of LLM‐generated dosing recommendations for cefepime and meropenem in patients with AKI and receiving CKRT. Methods: Six investigators queried the freely available versions of six LLMs (ChatGPT, Claude, Google Gemini, Microsoft Copilot, OpenEvidence, and Perplexity) from July to September 2025 using three standardized vignettes asking for dosing recommendations and rationale to meet prespecified pharmacodynamic targets: (i) adult with AKI not on dialysis receiving cefepime, (ii) child receiving CKRT and cefepime, and (iii) toddler receiving high‐effluent CKRT and meropenem. To assess inter‐iteration consistency, each investigator also prompted one LLM three times for each vignette. Responses were parsed for concordance with recommendations in primary literature. LLM “reasoning” was evaluated for use of pharmacokinetic (PK) equations, citation accuracy versus confabulation, acknowledgment of uncertainty, and recommendations for therapeutic drug monitoring (TDM) for efficacy or safety. Results: LLM‐generated dosing recommendations varied widely. Mean concordance with literature‐based recommendations was 63% (range: 28%–94%). LLMs produced variable responses to the same user upon multiple iterations, with variance in daily maintenance doses recommended ranging from 0 to 1000%. OpenEvidence universally cited relevant sources, whereas other LLMs leveraged sources inconsistently or confabulated them. Each recommended TDM, though only Claude consistently acknowledged its own uncertainty. Conclusion: Freely available LLMs produce highly variable and often discordant antibiotic dosing recommendations for patients with AKI and receiving CKRT. Although valuable for hypothesis generation and literature retrieval, LLM outputs should not be used in isolation for drug dosing in critically ill patients with kidney dysfunction.